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Methods

Background
Glutamine is an amino acid that is utilized by cancer
cells as a source of energy to replicate and spread. It
is the most abundant amino acid in plasma.
Glutamine is able to enter the cells through the
amino acid transporter ASCT2 (Neutral amino acid
transporter B(0)). V-9302 is a known competitive
inhibitor of ASCT2 and is capable of killing cancer
cells in vitro and in vivo. However, there have been
limitations to the usage of V-9302 due to toxicity in
vivo and its modest potency.
While there are many possibilities to enhance its
efficacy such as substitution with larger π-electron
rich aromatics or optimizing its pharmacophore, we
chose to explore the possibility of creating a
radiotherapeutic drug.
Recent studies have found that alpha emitting
radiotherapies have proven to have promising results
in clinical settings. Astatine-211 (²¹¹At) being an alpha
particle emitter of interest. This leads us to an
interest in an ²¹¹At labeled ASCT2 inhibitor analogue.

Conclusions

The analogue was synthesized using standard organic synthetic procedures (ether synthesis, reductive
amination, “click”-reaction and deprotection). The intermediates were isolated by normal phase silica column
(10-50% Ethyl acetate in hexane gradient) and the final products were purified by reverse phase (C-18) HPLC
(10-95% acetonitrile in water gradient over 35 min).

We successfully synthesized HA01 in six steps.
HA01’s efficacy as an ASCT2 inhibitor must now be
tested through a DARTS (Drug affinity responsive
target stability) assay. Assuming this assay is
successful - meaning the analogue properly binds to
ASCT2 - HA01 will be radiolabeled with an astatine
ion to be used for radiotherapy. To prepare for this, an
astatine ion will be attached to the location marked by
the blue circle below and then tested in a mouse
model.

Figure 2. Possibilities for changes and substitutions in V-9302.

Results
PHASE ONE – Sidechain synthesis
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Figure 4. HA01 ligand. Blue ellipses represents astatine binding site.

PHASE TWO – Condensation with pharmacophore
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PHASE THREE – Conjugation with radionuclide binding ligand
HA01
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Figure 1. Inhibition of ASCT2 (encoded by SLC1A5 gene) by V-9302.¹
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Synthesize a V-9302 analogue with equal or greater
affinity towards ASCT2 than V-9302 that can be used
for radiolabeling with ²¹¹At for radiotherapy in vivo.
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Figure 3. Synthesis of V-9302 analogue, HA01 ligand.
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